Home / Investors / Startups / ViewPoint Therapeutics

ViewPoint Therapeutics

ViewPoint Therapeutics is a developer of crystallin stabilizers intended to prevent and treat cataracts and presbyopia.

About ViewPoint Therapeutics

ViewPoint Therapeutics is a biotechnology company dedicated to the development of treatments for diseases of protein misfolding, including cataracts. The company's crystallin stabilizers include a small molecule that is active in preclinical models of age-related cataracts via a target-based screening and optimization effort, providing physicians with drugs to prevent or reverse protein misfolding, which is implicated in numerous common disorders of aging including cataracts, presbyopia, and neurodegenerative diseases.

Industries

Investors in ViewPoint Therapeutics (5)